SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for ChronoScale Holdings Corp (CHRN) (CIK 0001549084) (CHRN) — Jul 18, 2012

ChronoScale Holdings Corp (CHRN) (CIK 0001549084)
Date: July 18, 2012 · CIK: 0001549084 · Accession: 0000000000-12-037852

AI Filing Summary & Sentiment

File numbers found in text: 333-181229

Date
July 18, 2012
Author
Not clearly detected
Form
UPLOAD
Company
ChronoScale Holdings Corp (CHRN) (CIK 0001549084)

Letter

July 18, 2012 Via E-mail Pedro Perez Niklitschek President PN Med Group Inc. San Isidro 250, depot 618, Santiago, Chile 8240400 Re: PN Med Group Inc. Amendment No. 4 to Registra tion Statement on Form S-1 Filed July 11, 2012 File No. 333-181229

Dear Mr. Niklitschek: We have reviewed your registration statem ent and have the following comments. In some of our comments, we may ask you to provi de us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your re gistration statement and the information you provide in response to these comments, we may have additional comments.

Use of Proceeds, page 9

1. We note your response to comment 1 in our lett er dated July 9, 2012, and we reissue, in part, the comment. We note that you will a llocate $10,000 to legal and professional fees in all of your scenarios and your disclosure on page 10 that if you are unable to raise at least $25,000 you will allocate your proceeds as described in the $25,000 scenario. However, it remains unclear how you intend to use any additional proceeds if you raise less than $25,000. Please your use of proceeds section and your plan of operations to state, if true, that once you have paid your legal and professional fees of $25,000, you will allocate your proceeds pr oportionally to the other uses described in your $25,000 scenario.

Pedro Perez Niklitschek PN Med Group Inc. July 18, 2012 Page 2 We urge all persons who are responsible for th e accuracy and adequacy of the disclosure in the filing to be certain that the filing incl udes the information the Securities Act of 1933 and all applicable Securities Act rules require. Since the company and its management are in possession of all facts relating to a company’s disc losure, they are responsible for the accuracy and adequacy of the disclosures they have made. Notwithstanding our comments, in the event you request acceleration of the effective date of the pending registration statement please pr ovide a written statement from the company acknowledging that:  should the Commission or the staff, acting purs uant to delegated authority, declare the filing effective, it does not foreclose the Co mmission from taking any action with respect to the filing;

 the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 the company may not assert staff comments a nd the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Please refer to Rules 460 and 461 regarding re quests for acceleration. We will consider a written request for acceleration of the effective date of the regi stration statement as confirmation of the fact that those reques ting acceleration are aware of thei r respective responsibilities under the Securities Act of 1933 and the Securities Excha nge Act of 1934 as they relate to the proposed public offering of the securities specified in th e above registration stat ement. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. You may contact James Giug liano at (202) 551-3319 or Br ian Bhandari at (202) 551- 3390 if you have questions regarding comments on th e financial statements and related matters. Please contact Adam F. Turk at (202) 551-3657 or Pamela Howell at (202) 551-3357 with any other questions. Sincerely, /s/ Pamela Howell for John Reynolds Assistant Director

Show Raw Text
July 18, 2012

Via E-mail
Pedro Perez Niklitschek President PN Med Group Inc. San Isidro 250, depot 618, Santiago, Chile 8240400
Re: PN Med Group Inc.
  Amendment No. 4 to Registra tion Statement on Form S-1
Filed July 11, 2012
  File No. 333-181229

Dear Mr. Niklitschek:
 We have reviewed your registration statem ent and have the following comments.  In
some of our comments, we may ask you to provi de us with information so we may better
understand your disclosure.
 Please respond to this letter by amending your registration statement and providing the
requested information.  If you do not believe  our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
 After reviewing any amendment to your re gistration statement and the information you
provide in response to these comments, we may have additional comments.

Use of Proceeds, page 9

1. We note your response to comment 1 in our lett er dated July 9, 2012, and we reissue, in
part, the comment.  We note that you will a llocate $10,000 to legal and professional fees
in all of your scenarios and your  disclosure on page 10 that if you are unable to raise at
least $25,000 you will allocate your proceeds as  described in the $25,000 scenario.
However, it remains unclear how you intend to  use any additional proceeds if you raise
less than $25,000.  Please your use of proceeds section and your plan of operations to
state, if true, that once you have paid your legal and professional fees of $25,000, you
will allocate your proceeds pr oportionally to the other uses described in your $25,000
scenario.

Pedro Perez Niklitschek
PN Med Group Inc. July 18, 2012 Page 2
 We urge all persons who are responsible for th e accuracy and adequacy of the disclosure
in the filing to be certain that the filing incl udes the information the Securities Act of 1933 and
all applicable Securities Act rules require.  Since the company and its management are in
possession of all facts relating to a company’s disc losure, they are responsible for the accuracy
and adequacy of the disclosures they have made.
Notwithstanding our comments, in the event you request acceleration of  the effective date
of the pending registration statement please pr ovide a written statement from the company
acknowledging that:
 should the Commission or the staff, acting purs uant to delegated authority, declare the
filing effective, it does not foreclose the Co mmission from taking any action with respect
to the filing;

 the action of the Commission or the staff, acting pursuant to delegated authority, in
declaring the filing effective, does not relieve the company from its full responsibility for
the adequacy and accuracy of the disclosure in the filing; and

 the company may not assert staff comments a nd the declaration of effectiveness as a
defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Please refer to Rules 460 and 461 regarding re quests for acceleration.  We will consider a
written request for acceleration of  the effective date of the regi stration statement as confirmation
of the fact that those reques ting acceleration are aware of thei r respective responsibilities under
the Securities Act of 1933 and the Securities Excha nge Act of 1934 as they relate to the proposed
public offering of the securities specified in th e above registration stat ement.  Please allow
adequate time for us to review any amendment prior to the requested effective date of the
registration statement.
 You may contact James Giug liano at (202) 551-3319 or Br ian Bhandari at (202) 551-
3390 if you have questions regarding comments on th e financial statements and related matters.
Please contact Adam F. Turk at (202) 551-3657 or Pamela Howell at (202) 551-3357 with any
other questions.
Sincerely,
   /s/ Pamela Howell  for
John Reynolds Assistant Director